EU regulator conditionally approves Abbott's purchase of St Jude
- Donald Trump Sworn in as 45th U.S. President
- Wall Street ends higher as Trump becomes president
- Walgreens Boots Alliance (WBA) Said to Face Antitrust Concern for Rite Aid (RAD) Fix - Bloomberg
- Apple (AAPL) Sues Qualcomm (QCOM) Over Patent Royalties in Antitrust Case - Bloomberg
The ticker and trading information for St. Jude Medical is displayed where the stock is traded on the floor of the New York Stock Exchange (NYSE) in New York City, U.S., April 28, 2016. REUTERS/Brendan McDermid/File Photo
Get inside Wall Street with StreetInsider Premium. Claim your 2-week free trial here.
BRUSSELS (Reuters) - The European Commission on Wednesday said it has given its conditional approval to U.S. medical device maker Abbott Laboratories' (NYSE: ABT) bid for peer St Jude Medical Inc (NYSE: STJ).
Reuters reported on Nov. 15 that the $25 billion deal was going to be cleared in Brussels.
The European Commission, the mergers regulator, said in a statement that its approval was conditional on "Abbott divesting two devices used in cardiovascular treatments."
(Reporting by Gabriela Baczynska)
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Abbott Labs (ABT) PT Raised to $48 at Jefferies
- Gambia's longtime leader Jammeh says he will step down
- Morgan Stanley CEO James Gorman's 2016 pay up 7 pct to $22.5 million